10-K Filing

MERCK & CO., INC. CIK: 310158 FY 2017

Filing Information

Form Type	10-K
Accession Number	`0000310158-18-000005`
Period End Date	20171231
Filing Date	20180227
Fiscal Year	2017
Fiscal Period	FY
XBRL Instance	mrk-20171231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 92 Income Statement 42 Cash Flow Statement 126 Stockholders Equity 35 Comprehensive Income 21

Balance Sheet 92 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$195.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$210.00M	USD	Point-in-time
Inventories classified in other assets	`InventoryNoncurrent`	$1.12B	USD	Point-in-time
Inventories classified in other assets	`InventoryNoncurrent`	$1.19B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.52B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.44B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.09B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.51B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$7.83B	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$2.41B	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $210 in 2017 and $195 in 2016)	`AccountsReceivableNetCurrent`	$7.02B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $210 in 2017 and $195 in 2016)	`AccountsReceivableNetCurrent`	$6.87B	USD	Point-in-time
Inventories (excludes inventories of $1,187 in 2017 and $1,117 in 2016 classified in Other assets - see Note 7)	`InventoryNet`	$5.10B	USD	Point-in-time
Inventories (excludes inventories of $1,187 in 2017 and $1,117 in 2016 classified in Other assets - see Note 7)	`InventoryNet`	$4.87B	USD	Point-in-time
Treasury stock, shares (in shares)	`TreasuryStockShares`	880.49M	shares	Point-in-time
Treasury stock, shares (in shares)	`TreasuryStockShares`	828.37M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$4.39B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$4.30B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$24.77B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$30.61B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$11.42B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$12.12B	USD	Point-in-time
Land	`Land`	$412.00M	USD	Point-in-time
Land	`Land`	$365.00M	USD	Point-in-time
Buildings	`BuildingsAndImprovementsGross`	$11.73B	USD	Point-in-time
Buildings	`BuildingsAndImprovementsGross`	$11.44B	USD	Point-in-time
Machinery, equipment and office furnishings	`MachineryAndEquipmentGross`	$14.65B	USD	Point-in-time
Machinery, equipment and office furnishings	`MachineryAndEquipmentGross`	$14.05B	USD	Point-in-time
Construction in progress	`ConstructionInProgressGross`	$2.30B	USD	Point-in-time
Construction in progress	`ConstructionInProgressGross`	$1.87B	USD	Point-in-time
Property, plant and equipment (at cost)	`PropertyPlantAndEquipmentGross`	$29.04B	USD	Point-in-time
Property, plant and equipment (at cost)	`PropertyPlantAndEquipmentGross`	$27.77B	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$15.75B	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$16.60B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$12.44B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$12.51B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$12.03B	USD	Point-in-time
Goodwill	`Goodwill`	$17.72B	USD	Point-in-time
Goodwill	`Goodwill`	$18.28B	USD	Point-in-time
Goodwill	`Goodwill`	$18.16B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$17.30B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$14.18B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$6.08B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$5.85B	USD	Point-in-time
Total Assets	`Assets`	$95.38B	USD	Point-in-time
Total Assets	`Assets`	$87.87B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$3.06B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$568.00M	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$2.81B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.10B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$10.27B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$10.43B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$2.24B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$708.00M	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.32B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.32B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$17.20B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$18.61B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$24.27B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$21.35B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$2.22B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$5.08B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$11.12B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.51B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2017 and 2016	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2017 and 2016	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$39.90B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$39.94B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$41.35B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$44.13B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.91B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.23B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$80.63B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$78.13B	USD	Point-in-time
Less treasury stock, at cost: 880,491,914 shares in 2017 and 828,372,200 shares in 2016	`TreasuryStockValue`	$40.55B	USD	Point-in-time
Less treasury stock, at cost: 880,491,914 shares in 2017 and 828,372,200 shares in 2016	`TreasuryStockValue`	$43.79B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$40.09B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$34.34B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$233.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$220.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$40.31B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.57B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$48.79B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$44.77B	USD	Point-in-time
Total Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$95.38B	USD	Point-in-time
Total Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$87.87B	USD	Point-in-time

Income Statement 42 line items

Line Item	Tag	Value	Unit	Period
Sales	`SalesRevenueGoodsNet`	$39.50B	USD	Annual
Sales	`SalesRevenueGoodsNet`	$39.81B	USD	Annual
Sales	`SalesRevenueGoodsNet`	$40.12B	USD	Annual
Materials and production	`CostOfGoodsSold`	$12.78B	USD	Annual
Materials and production	`CostOfGoodsSold`	$14.93B	USD	Annual
Materials and production	`CostOfGoodsSold`	$13.89B	USD	Annual
Marketing and administrative	`SellingGeneralAndAdministrativeExpense`	$9.83B	USD	Annual
Marketing and administrative	`SellingGeneralAndAdministrativeExpense`	$10.31B	USD	Annual
Marketing and administrative	`SellingGeneralAndAdministrativeExpense`	$9.76B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$10.21B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$6.70B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$10.12B	USD	Annual
Restructuring costs	`RestructuringCharges`	$776.00M	USD	Annual
Restructuring costs	`RestructuringCharges`	$619.00M	USD	Annual
Restructuring costs	`RestructuringCharges`	$651.00M	USD	Annual
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-12.00M	USD	Annual
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-1.53B	USD	Annual
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-720.00M	USD	Annual
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$34.10B	USD	Annual
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$33.60B	USD	Annual
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$35.15B	USD	Annual
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$5.40B	USD	Annual
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$6.52B	USD	Annual
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$4.66B	USD	Annual
Taxes on Income	`IncomeTaxExpenseBenefit`	$942.00M	USD	Annual
Taxes on Income	`IncomeTaxExpenseBenefit`	$4.10B	USD	Annual
Taxes on Income	`IncomeTaxExpenseBenefit`	$718.00M	USD	Annual
Net Income	`ProfitLoss`	$2.42B	USD	Annual
Net Income	`ProfitLoss`	$4.46B	USD	Annual
Net Income	`ProfitLoss`	$3.94B	USD	Annual
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$21.00M	USD	Annual
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$17.00M	USD	Annual
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$24.00M	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.44B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.92B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.39B	USD	Annual
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$0.88	USD	Annual
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.58	USD	Annual
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.42	USD	Annual
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.41	USD	Annual
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.56	USD	Annual
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$0.87	USD	Annual

Cash Flow Statement 126 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$2.42B	USD	Annual
Net income	`ProfitLoss`	$4.46B	USD	Annual
Net income	`ProfitLoss`	$3.94B	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$6.38B	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$4.64B	USD	Annual
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$5.44B	USD	Annual
Intangible asset impairment charges	`AssetImpairmentCharges`	$646.00M	USD	Annual
Intangible asset impairment charges	`AssetImpairmentCharges`	$162.00M	USD	Annual
Intangible asset impairment charges	`AssetImpairmentCharges`	$3.95B	USD	Annual
Provisional charge for one-time transition tax related to the enactment of U.S. tax legislation	`TaxCutsandJobsActof2017IncompleteAccountingTransitionTaxforAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit`	-	USD	Annual
Provisional charge for one-time transition tax related to the enactment of U.S. tax legislation	`TaxCutsandJobsActof2017IncompleteAccountingTransitionTaxforAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit`	$5.35B	USD	Annual
Provisional charge for one-time transition tax related to the enactment of U.S. tax legislation	`TaxCutsandJobsActof2017IncompleteAccountingTransitionTaxforAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit`	-	USD	Annual
Charge for future payments related to AstraZeneca collaboration license options	`ChargeForLicenseOptionsRelatedToCollaboration`	-	USD	Annual
Charge for future payments related to AstraZeneca collaboration license options	`ChargeForLicenseOptionsRelatedToCollaboration`	-	USD	Annual
Charge for future payments related to AstraZeneca collaboration license options	`ChargeForLicenseOptionsRelatedToCollaboration`	$500.00M	USD	Annual
Charge related to the settlement of worldwide Keytruda patent litigation	`GainLossRelatedToLitigationSettlement`	-	USD	Annual
Charge related to the settlement of worldwide Keytruda patent litigation	`GainLossRelatedToLitigationSettlement`	-	USD	Annual
Charge related to the settlement of worldwide Keytruda patent litigation	`GainLossRelatedToLitigationSettlement`	$-625.00M	USD	Annual
Charge related to the settlement of worldwide Keytruda patent litigation	`GainLossRelatedToLitigationSettlement`	$-80.00M	USD	Point-in-time
Foreign currency devaluation related to Venezuela	`ForeignCurrencyTransactionGainLossRealized`	-	USD	Annual
Foreign currency devaluation related to Venezuela	`ForeignCurrencyTransactionGainLossRealized`	$-876.00M	USD	Annual
Foreign currency devaluation related to Venezuela	`ForeignCurrencyTransactionGainLossRealized`	-	USD	Annual
Net charge related to the settlement of Vioxx shareholder class action litigation	`UnusualOrInfrequentItemNetOfInsuranceProceeds`	-	USD	Annual
Net charge related to the settlement of Vioxx shareholder class action litigation	`UnusualOrInfrequentItemNetOfInsuranceProceeds`	$680.00M	USD	Annual
Net charge related to the settlement of Vioxx shareholder class action litigation	`UnusualOrInfrequentItemNetOfInsuranceProceeds`	-	USD	Annual
Equity income from affiliates	`IncomeLossFromEquityMethodInvestments`	$86.00M	USD	Annual
Equity income from affiliates	`IncomeLossFromEquityMethodInvestments`	$42.00M	USD	Annual
Equity income from affiliates	`IncomeLossFromEquityMethodInvestments`	$205.00M	USD	Annual
Dividends and distributions from equity method affiliates	`EquityMethodInvestmentDividendsOrDistributions`	$2.00M	USD	Annual
Dividends and distributions from equity method affiliates	`EquityMethodInvestmentDividendsOrDistributions`	$50.00M	USD	Annual
Dividends and distributions from equity method affiliates	`EquityMethodInvestmentDividendsOrDistributions`	$16.00M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-1.52B	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-764.00M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-2.62B	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$299.00M	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$312.00M	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$300.00M	USD	Annual
Other	`OtherNoncashIncomeExpense`	$-269.00M	USD	Annual
Other	`OtherNoncashIncomeExpense`	$-313.00M	USD	Annual
Other	`OtherNoncashIncomeExpense`	$-874.00M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$480.00M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$619.00M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-297.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$-805.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$-206.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$145.00M	USD	Annual
Trade accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$-37.00M	USD	Annual
Trade accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$254.00M	USD	Annual
Trade accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$278.00M	USD	Annual
Accrued and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-2.02B	USD	Annual
Accrued and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-8.00M	USD	Annual
Accrued and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-922.00M	USD	Annual
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$-3.29B	USD	Annual
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$-266.00M	USD	Annual
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$124.00M	USD	Annual
Noncurrent liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-277.00M	USD	Annual
Noncurrent liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-809.00M	USD	Annual
Noncurrent liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-123.00M	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingCapitalNet`	$1.09B	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingCapitalNet`	$5.00M	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-237.00M	USD	Annual
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$10.38B	USD	Annual
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$12.54B	USD	Annual
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$6.45B	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$1.89B	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$1.61B	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$1.28B	USD	Annual
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$15.65B	USD	Annual
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$16.68B	USD	Annual
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$10.74B	USD	Annual
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$14.35B	USD	Annual
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$15.66B	USD	Annual
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$20.41B	USD	Annual
Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	Annual
Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$7.60B	USD	Annual
Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	Annual
Acquisitions of other businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$396.00M	USD	Annual
Acquisitions of other businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$780.00M	USD	Annual
Acquisitions of other businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$146.00M	USD	Annual
Dispositions of businesses, net of cash divested	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	$316.00M	USD	Annual
Dispositions of businesses, net of cash divested	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	-	USD	Annual
Dispositions of businesses, net of cash divested	`ProceedsFromDivestitureOfBusinessesNetOfCashDivested`	-	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-221.00M	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-482.00M	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-38.00M	USD	Annual
Net Cash Provided by (Used in) Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$2.68B	USD	Annual
Net Cash Provided by (Used in) Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-4.76B	USD	Annual
Net Cash Provided by (Used in) Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-3.21B	USD	Annual
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	-	USD	Annual
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$-26.00M	USD	Annual
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$-1.54B	USD	Annual
Payments on debt	`RepaymentsOfLongTermDebt`	$1.10B	USD	Annual
Payments on debt	`RepaymentsOfLongTermDebt`	$2.91B	USD	Annual
Payments on debt	`RepaymentsOfLongTermDebt`	$2.39B	USD	Annual
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$1.08B	USD	Annual
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$7.94B	USD	Annual
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	Annual
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$4.19B	USD	Annual
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$3.43B	USD	Annual
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$4.01B	USD	Annual
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$5.12B	USD	Annual
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$5.17B	USD	Annual
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$5.12B	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$939.00M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$499.00M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$485.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-195.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-61.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-118.00M	USD	Annual
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-9.04B	USD	Annual
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-5.39B	USD	Annual
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-10.01B	USD	Annual
Effect of Exchange Rate Changes on Cash and Cash Equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-131.00M	USD	Annual
Effect of Exchange Rate Changes on Cash and Cash Equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$457.00M	USD	Annual
Effect of Exchange Rate Changes on Cash and Cash Equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-1.31B	USD	Annual
Net (Decrease) Increase in Cash and Cash Equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-2.01B	USD	Annual
Net (Decrease) Increase in Cash and Cash Equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$1.08B	USD	Annual
Net (Decrease) Increase in Cash and Cash Equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-423.00M	USD	Annual
Cash and Cash Equivalents at Beginning of Year	`CashAndCashEquivalentsAtCarryingValue`	$8.52B	USD	Point-in-time
Cash and Cash Equivalents at Beginning of Year	`CashAndCashEquivalentsAtCarryingValue`	$7.44B	USD	Point-in-time
Cash and Cash Equivalents at Beginning of Year	`CashAndCashEquivalentsAtCarryingValue`	$6.09B	USD	Point-in-time
Cash and Cash Equivalents at Beginning of Year	`CashAndCashEquivalentsAtCarryingValue`	$6.51B	USD	Point-in-time
Cash and Cash Equivalents at End of Year	`CashAndCashEquivalentsAtCarryingValue`	$8.52B	USD	Point-in-time
Cash and Cash Equivalents at End of Year	`CashAndCashEquivalentsAtCarryingValue`	$7.44B	USD	Point-in-time
Cash and Cash Equivalents at End of Year	`CashAndCashEquivalentsAtCarryingValue`	$6.09B	USD	Point-in-time
Cash and Cash Equivalents at End of Year	`CashAndCashEquivalentsAtCarryingValue`	$6.51B	USD	Point-in-time

Stockholders Equity 35 line items

Line Item	Tag	Value	Unit	Period
Common stock, dividends declared (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$1.85	USD	Annual
Common stock, dividends declared (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$1.81	USD	Annual
Common stock, dividends declared (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$1.89	USD	Annual
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$40.31B	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.57B	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$48.79B	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$44.77B	USD	Point-in-time
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.44B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.92B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.39B	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$316.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$175.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$-1.08B	USD	Annual
Cash dividends declared on common stock ($1.89 per share in 2017, $1.85 per share in 2016 and $1.81 per share in 2015)	`DividendsCommonStockCash`	$5.13B	USD	Annual
Cash dividends declared on common stock ($1.89 per share in 2017, $1.85 per share in 2016 and $1.81 per share in 2015)	`DividendsCommonStockCash`	$5.12B	USD	Annual
Cash dividends declared on common stock ($1.89 per share in 2017, $1.85 per share in 2016 and $1.81 per share in 2015)	`DividendsCommonStockCash`	$5.18B	USD	Annual
Treasury stock shares purchased	`TreasuryStockValueAcquiredCostMethod`	$4.01B	USD	Annual
Treasury stock shares purchased	`TreasuryStockValueAcquiredCostMethod`	$4.19B	USD	Annual
Treasury stock shares purchased	`TreasuryStockValueAcquiredCostMethod`	$3.43B	USD	Annual
Changes in noncontrolling ownership interests	`MinorityInterestDecreaseFromRedemptions`	$-75.00M	USD	Annual
Changes in noncontrolling ownership interests	`NoncontrollingInterestIncreaseFromBusinessCombination`	$7.00M	USD	Annual
Changes in noncontrolling ownership interests	`NoncontrollingInterestIncreaseFromBusinessCombination`	$124.00M	USD	Annual
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$21.00M	USD	Annual
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$17.00M	USD	Annual
Net income attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$24.00M	USD	Annual
Distributions attributable to noncontrolling interests	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$16.00M	USD	Annual
Distributions attributable to noncontrolling interests	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$15.00M	USD	Annual
Distributions attributable to noncontrolling interests	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$18.00M	USD	Annual
Share-based compensation plans and other	`StockholdersEquityOther`	$1.14B	USD	Annual
Share-based compensation plans and other	`StockholdersEquityOther`	$729.00M	USD	Annual
Share-based compensation plans and other	`StockholdersEquityOther`	$733.00M	USD	Annual
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$40.31B	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.57B	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$48.79B	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$44.77B	USD	Point-in-time

Comprehensive Income 21 line items

Line Item	Tag	Value	Unit	Period
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.44B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.92B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.39B	USD	Annual
Net unrealized loss on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax`	$-66.00M	USD	Annual
Net unrealized loss on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax`	$-446.00M	USD	Annual
Net unrealized loss on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax`	$-126.00M	USD	Annual
Net unrealized loss on investments, net of reclassifications	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-44.00M	USD	Annual
Net unrealized loss on investments, net of reclassifications	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-70.00M	USD	Annual
Net unrealized loss on investments, net of reclassifications	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-58.00M	USD	Annual
Benefit plan net gain (loss) and prior service credit (cost), net of amortization	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$799.00M	USD	Annual
Benefit plan net gain (loss) and prior service credit (cost), net of amortization	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$-419.00M	USD	Annual
Benefit plan net gain (loss) and prior service credit (cost), net of amortization	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$-579.00M	USD	Annual
Cumulative translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-169.00M	USD	Annual
Cumulative translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$401.00M	USD	Annual
Cumulative translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-208.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$316.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$175.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$-1.08B	USD	Annual
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$2.71B	USD	Annual
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$4.62B	USD	Annual
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$2.84B	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.